Ozempic, the diabetes treatment often prescribed for weight loss, is also proving highly-effective in treating patients with chronic kidney disease.
Novo Nordisk, the Danish drugmaker behind the popular weight loss treatment Ozempic, said Wednesday that it has also proven to be a highly-effective in treading kidney failure.
Shares in the group soared to the top of the European stock market Wednesday after its stopped a trial of the drug on kidney patients one year early, citing data from the study that showed clear success in slowing the advance of chronic kidney disease while lowering the risk of associated heart risk.
"The decision to stop the trial is based on a recommendation from the independent Data Monitoring Committee concluding that the results from an interim analysis met certain pre-specified criteria for stopping the trial early for efficacy," Novo Nordisk said."Based on the decision to stop the trial at interim, the process of closing the trial will be initiated."
Novo Nordisk is also the maker of Wegovy, another weight-loss treatment that uses the active ingredient semaglutide, also found in Ozempic, that can stimulate insulin production.diabetes and obesity treatment, Mounjaro, which the drugmaker is also hoping will be prescribed as a broader weight loss treatment.
Novo Nordisk's U.S.-listed shares were marked 2.4% higher in pre-market trading to indicate an opening bell price of $95.25 each, while Eli Lilly shares were marked 2.13% higher at $591.66 each.
Indonesia Berita Terbaru, Indonesia Berita utama
Similar News:Anda juga dapat membaca berita serupa dengan ini yang kami kumpulkan dari sumber berita lain.
Novo Nordisk stops Ozempic kidney trial after early signs of successNovo Nordisk (NOVOb.CO) said on Tuesday it will stop a trial studying Ozempic to treat kidney failure in diabetes patients ahead of schedule because it was clear from an interim analysis that the treatment would succeed.
Baca lebih lajut »
How Ozempic and Wegovy turned Novo Nordisk into a $400 billion companyHow Ozempic and Wegovy turned Novo Nordisk into a $400 billion company
Baca lebih lajut »
Stock movers: Novo Nordisk, Fresenius Medical Care, DaVita, Thor IndustriesNovo Nordisk, Thor Industries, Silk Road Medical, Fresenius Medical Care, and DaVita all showed stock price movement in pre-market trading
Baca lebih lajut »
Novo Nordisk Halts Ozempic Kidney Trial. Why It's Bad for DaVita Stock.Novo Nordisk’s Ozempic already is poised to disrupt a range of industries via its weight-loss benefits. Now it threatens companies which treat kidney failure.
Baca lebih lajut »
FDA Adds Warning To Ozempic Label About Ileus, Intestinal BlockageI am a writer, journalist, professor, systems modeler, computational, AI, and digital health expert, medical doctor, avocado-eater, and entrepreneur, not always in that order. Currently, I am a Professor of Health Policy and Management at the City University of New York (CUNY) School of Public Health, Executive Director of PHICOR (PHICORteam) and Center for Advanced Technology and Communication in Health (CATCH), and founder and CEO of Symsilico. My previous positions include serving as Profess
Baca lebih lajut »
Oprah Winfrey walks back criticism of Ozempic users after WeightWatchers touts drugWinfrey’s comments last month led to WeightWatchers stock nosediving by as much as 15% the next day.
Baca lebih lajut »